1. Introduction
1.1. Epidemiology of social anxiety disorder (SAD)
SAD, also known as social phobia, is characterised by excessive fear of embarrassment or humiliation in social situations, which in turn leads to marked distress or avoidance of these situations and functional impairment as described in DSM-IV-TR.
It is a common disorder with early onset, significant comorbidity and functional impairment (Meron Ruscia et al., 2008).
SAD has been ranked as one of the top ten chronic disorders – mental or physical – in terms of its effects on objective outcomes, such as days of work lost and reduced health-related quality of life (Alonso, 2004). According to the National Comorbidity Survey, SAD is the most reported anxiety disorder and has a lifetime prevalence of 12% (Kessler et al., 2005), with considerable coexisting psychiatric disorders, such as depression, anxiety, and substance-related disorders.Lifetime prevalence of social anxiety disorder among Turkish university students was 23% (Dilbaz 2006). Co-occurring SAD and depression carry a substantial risk of suicide, which further complicates treatment (Beesdo et al., 2007; Thase, 2007). SAD symptoms normally emerge during early adolescence and continue throughout adulthood; they affect women more often than men (Fehm et al., 2005).In clinical samples the ratio of male and female changes in the favour of males. (Dilbaz and Güz 2002). Trials suggest that social anxiety even below the diagnostic threshold is clearly associated with adverse outcomes like elevated risk for comorbid disorders and associated with impairment in diverse areas of life.
Despite the growing understanding of this condition, information is lacking on key aspects of the disorder and many individuals, including doctors, psychiatrists and patients, unaware about this condition.
1.2. Children and adolescents
SAD, which so often begins in childhood, precedes other comorbid disorders and may be a direct or indirect risk factor for other disorders, such as depression and substance abuse. Epidemiologic findings show that in the pediatric primary healthcare setting anxiety disorders are very common ranging from 1% to 10% (Briggs-Gowan et al., 2000; Busch et al., 2002; Costello, 1989), but are unrecognized and under-treated (Chavira et al., 2004; Wren et al., 2003). In community settings, rates of SAD in youth range from 0.5% to 4% (Essau et al., 1999; Wittchen et al., 1998) and from 3% to 6.8% in primary care settings (Busch et al., 2002; Costello, 1989; Chavira et al., 2004). Recent research suggest that lifetime prevalence rates in adolescents in the US and Germany are between 5% and 15% (Heimberg et al., 2000; Lewinsohn et al., 1993). Although the age of onset is usually in the early teens with a mean age of onset of 15.5 years (Schneider et al., 1993) children as young as 8 years old have been diagnosed with the disorder (Beidel & Turner, 1998).
Shyness, behavioral inhibition and selective mutism can be considered in spectrum of social anxiety disorder in childhood. Children who are rated by their parents as having a shy temperament in infancy or in early childhood had an approximately 2 or 3 times increased probability of having an anxiety disorder in adolescence (Prior et al, 2000). In a five year longitudinal study, researchers found that behavioral inhibition-which can be described as a tendency to demonstrate fearfulness or resistance when faced with an unfamiliar stimuli, in pre-school children appeared to be a predictor for social anxiety in middle school (Hirshfeld-Becker et al., 2007). Selective mutism can be considered an extreme form of social anxiety including features of shyness and behavioral inhibition, where the most prominent feature is the inhibition of speech in select situations. Comorbidity rates between selective mutism and social anxiety disorder range from 70–95% (Dummit et al., 1997; Black & Uhde, 1995) and characteristics such as shyness, anxiousness, withdrawal and seriousness are used to describe both selective mutism and social anxiety alike (Steinhausen & Juzi, 1996; Kumpulainen et al., 1998).
Studies have shown that in children aged 7–13 years with SAD, 60% had an additional psychiatric diagnosis, of whom 36% had an anxiety disorder as follows: generalized anxiety disorder 10%; attention deficit hyperactivity disorder 10%; specific phobia 10%; and selective mutism 8% (Biedel et al., 1999). Those individuals who develop comorbid disorders will also have an increased risk of suicidal ideation and suicide attempts.
In treatment of social anxiety disorders in childhood and adolecence, most practitioners advise the initial use of psychological interventions followed by pharmacotherapy when necessary. Specific treatments have employed cognitive-behavioral group therapy for SAD in adolescents, social effectiveness therapy for children (Beidel et al., 2000) and ‘coping cat’ child behavior therapy (Flannery-Schroeder et al., 2000). Overall, most clinical researchers now believe that CBT is the treatment of choice for youth with internalizing disorders including SAD (March et al., 2003).
There are very few pharmacotherapy trials in general and even fewer randomized, double-blind, placebo-controlled trials in childhood anxiety disorders. Studies with both open-label and double blind placebo control groups have shown promising results ranging from 36–100% success rates (Compton et al., 2001; Mancini et al., 1999). Selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) are defined as first line pharmacotherapy for social anxiety disorders in youth with a careful assessessment of suicidal ideation before starting these antidepressants.
The development of comorbid mental disorders such as depression and substance abuse, children and adolescents with this illness are at risk for educational or occupational under-achievement, and failure to achieve financial and emotional independence. The challenge of preventing the consequences of SAD lies in early diagnosis.
2. Organic etiology of SAD
Although the etiology of SAD is poorly understood, emerging evidence indicates multidimensional causes. It is a distinct psychiatric disorder with genetic underpinnings and is associated with neurobiological and environmental mechanisms.
Over the past two decades, numerous neurobiological methods have been used in studies of SAD including structural, functional and receptor brain imaging, pharmacological trials, candidate gene investigations and studies of psychophysiological, endocrine, biochemical and behavioral responses to stressful challenges. It has been hypothesized that affect regulation is compromised in individuals with SAD, either due to hyperactivity in emotion triggering areas like the amygdala and insula, or hypoactivity in modulatory regions like the anterior cingulate and prefrontal cortices. It also has been hypothesized that SAD patients would show exaggerated amygdala responses to angry or threatening faces in comparison to healthy control subjects and that amygdala hyperresponsivity is associated with enhanced fear conditionability in SAD (Furmark, 2009).
A range of neurotransmitters may be important in SAD including the monoamines, glutamate, GABA, and several neuropeptides, but to date, the serotonergic and dopaminergic transmission systems have received most of the attention.
Serotonin has been implicated in animal models of fear and anxiety (Graeff, 2002) and the therapeutic efficacy of SSRIs (Ipser et al., 2008) strongly suggests that serotonin has a crucial role in SAD. Allelic variation in serotonin-related genes modulate amygdala responsivity both in healthy volunteers (Hariri & Holmes, 2006) and in patients with SAD (Furmark et al., 2004). Lanzenberger et al. demonstrated a significantly lower serotonin-1A receptor binding potential in SAD patients relative to controls in the amygdala, anterior cingulate cortex, insula, and dorsal raphe nuclei in their PET study (Lanzenberger et al., 2007). Serotonergic involvement is also supported by neuroendocrine challenges studies (Tancer, 1993).
Dopamine is known to play a central role in motivation and reward-seeking behaviors and several lines of evidence point to a dysfunction of this transmitter system in SAD like patients with Parkinson’s Disease, which is associated with dopamine hypofunction, appear to have enhanced risk for developing SAD (Richard et al., 1996). Abnormal central dopaminergic neurotransmission has also been reported in animal trials relevant to SAD, such as studies of social subordination in primates (Grant et al., 1998). Two independent SPECT studies also point directly to an altered dopamine system activity in SAD. Tiihonen et al. reported that the striatal dopamine reuptake site density was markedly lower in patients with SAD than controls, presumably reflecting a smaller number of dopaminergic synapses and neurons in the basal ganglia (Tiihonen et al., 1997). Schneier et al. also observed that striatal dopamine D2 receptor binding was significantly lower in subjects with SAD than in comparison subjects (Schneier et al., 2000).
Genetically-oriented studies of SAD and related constructs such as behavioral inhibition, neuroticism, introversion and harm-avoidance suggest that genetic factors play at least a moderate role in the etiology of excessive social anxiety (Stein et al., 1994). The short (s) allele of the promoter polymorphism of the human serotonin transporter gene (the 5-HTT-linked polymorphic region; 5-HTTLPR) has been associated with anxiety-related personality traits, increased fear conditionability, and life-stress-induced aff ective disorder (Serretti et al., 2006). Several other genotypes influence amygdala responsivity and could thus be considered in future studies of SAD, for example the tryptophan hydroxylase-2 gene (G-703T polymorphism) (Brown et al., 2005) and the catechol-Omethyltransferase gene (COMT Val158Met) (Smolka et al., 2005).
3. Diagnosis and assessment of SAD
The first challenge in the treatment of SAD is making a correct diagnosis. There is evidence that SAD is under-diagnosed and under-treated in primary care and specialist settings alike (Katzelnick & Greist, 2001). Possible reasons for this may be lack of diagnostic awareness, lack of diagnostic threshold clarity or the presence of co-morbid disorders. Moreover, as consultation with a clinician may be perceived as social interaction, the nature of the disorder may cause patients to delay seeking help, and when they eventually do, it is often with physical complaints or psychiatric comorbidity.
During the initial evaluation it is important to find out severity of symptoms as well as the degree of avoidance and functional impairment present. Rating scales such as the Liebowitz social anxiety scale that is translated and validated to Turkish also, may be helpful in assessing both feared situations and avoidance and can be used to monitor the patient’s treatment progress (Liebowitz 1987, Dilbaz and Guz ). A range of other SAD scales are also available, like the Brief Social Phobia Scale (clinician rated) and the Social Phobia Inventory (patient rated) (Davidson et al., 1997; Conner et al., 2000).
4. Co-morbidity
Significant comorbidity of social anxiety and mood disorders have been consistently shown in the literature (Kessler et al., 1999; Lecrubier & Weiller, 1997; Pini et al. 1997). Social anxiety has also been linked to severity (Merikangas & Angst, 1995) and persistence (Alpert et al. 1997) of mood disorders. Also comorbid mood disorders have worsen social anxiety symptoms and result in greater impairment in patients with SAD (Erwin et al., 2002). A significant number of patients presenting with social anxiety will have a secondary anxiety disorder, particularly panic disorder with agoraphobia and generalized anxiety disorder (Mennin et al. 2000, Schneier et al., 1992). Comorbid depressive or anxiety disorders complicate SAD, the severity of symptoms and suicidality should be assessed and hospitalisation considered if indicated. In such cases, the treatment of choice should ideally target both the mood and the anxiety components.
Social phobia and avoidant personality disorder were introduced in the DSM classification system nearly 30 years ago. Since then it has been shown that these two disorders can be found highly comorbid in patients, in some trials as high as 89% (Schneier et al., 1991). Some researchers have interpreted this high rate of overlap to mean that social phobia and avoidant personality disorder reflect a spectrum of social anxiety (Tillfors & Ekselius, 2009).
Social anxiety disorder is associated with high rates of alcohol use disorders (Morris et al., 2005). Almost half of the patients with lifetime SAD meet criteria for lifetime prevalence of an alcohol use disorder (Grant et al.,2005) and it is a significantly high rate when compared to general population. Among the anxiety disorders, SAD shows a particularly problematic risk profile for comorbid alcohol use disorders, as SAD is associated with higher rates of alcohol use disorders relative to most other anxiety disorders (Kessler et al.,1997).
Recently, researchers have identified that individuals with SAD appear particularly vulnerable to marijuana-related problems too. Data from the National Comorbidity Study suggest that individuals with SAD are 7 times more likely to experience marijuana dependence relative to the general population (Agosti et al, 2002) and undergraduates with higher social anxiety appear to be particularly vulnerable to marijuana use problems (Buckner et al, 2007; Buckner et al., 2008a). In a study, adolescents with SAD were nearly 5 times more likely to develop marijuana dependence as young adults compared to adolescents without SAD (Buckner et al., 2008b).
5. Treatment of SAD
Current recommended treatment options for social anxiety disorder include pharmacotherapy and cognitive behavioural therapy (CBT). (Dilbaz 2005) Although several randomised controlled trials (RCTs) have failed to show efficacy for β-adrenoceptor antagonists in generalised SAD, it has been suggested that these agents may be useful in non-generalised SAD, patients with performance anxiety only. Efficacy in the treatment of generalised SAD has been demonstrated for a number of interventions, (Stein, 2003; Blanco et al., 2003) including SSRIs, high potency benzodiazepines (e.g. clonazepam), MAOIs (e.g. phenelzine), reversible inhibitors of monoamine oxidase A (MAO-A) [RIMAs, e.g. moclobemide], certain antiepileptics (e.g. gabapentin, pregabalin), serotonin-noradrenaline reuptake inhibitors (venlafaxine) and CBT (Zaider & Heimberg 2003).
5.1. Nonpharmacological treatments
These treatments include exposure, cognitive re-structuring, relaxation techniques and social skills training, often used in combination. Literature have concluded that cognitive behavioral therapy (CBT) is often effective for treating social anxiety disorder. The goal of cognitive behavioral therapy (CBT) is to provide techniques and practice to patients with social anxiety disorder, so they can learn to change how they think about and behave in situations that terrify them. CBT may be offered individually or as part of group therapy. There is continued interest in the question of whether group or individual treatment is more effective. Early studies suggested some superiority for group treatment (Wlazlo et al., 1990), and arguments were raised that the group setting would provide a richness of exposure experiences not easily replicated in individual treatment; by the late 1990s the weight of evidence suggested that there was no clear superiority between group and individual treatment (Gould et al., 1997).
Meta-analyses of the efficacy of CBT for SAD that have compared various types of CBT with each other and with control conditions have yielded the highest effect sizes for exposure-based interventions (Federof & Taylor, 2001; Hope et al.,1995). In exposure therapy, the type of CBT most often used and studied for social anxiety disorder, therapists gradually expose patients to the dreaded situation and suggest ways to manage fear. The exposure-based extinction of fear is now thought to involve new learning that actively inhibits the fear reaction to a given cue (Davis et al., 2006). In other variations of CBT— not as well studied as exposure therapy— patients learn and practice social skills and relaxation techniques.
5.2. Pharmacological treatments
5.3. Inadequate response to pharmacotherapy and augmentation strategies
Criteria for remission of SAD proposed by Ballenger (Ballenger, 2001) include absence of core symptoms of SAD, no or minimal anxiety (e.g. in anticipation of social interaction) as rated by rating scales such as the Hamilton Rating Scale for Anxiety, no functional impairment (the Sheehan Disability Scale may be used to evaluate this), (Sheehan et al., 1996) and remission of course of action when first-line treatment with a co-morbid depression as reflected by the Hamilton Rating Scale for Depression. It should, however, be noted that the mean reduction in Liebowitz Social Anxiety Scale scores was <50% in a review of 19 double-blind, placebo-controlled trials involving patients with SAD. Switching to another SSRIs, venlafaxine or MAOIs has been suggested in non responders or patients with adverse event. Augmentation strategies that may prove useful in partial treatment responders include buspirone, clonazepam, gabapentin, bupropion or new generation antipsychotics, although empirical data are lacking (Barnett et al., 2002; Schutters et al., 2005; Pallanti et al., 1999).
In case of comorbidity moclobemide was found to be effective and well-tolerated in the SAD patients with anxiety disorders as well as SSRIs. In the presence of co-morbid alcohol abuse, MAOIs and benzodiazepines can complicate the treatment, SSRIs have usefulness in reducing the alcohol consumption (Naranjo & Knoke, 2001). CBT may be the treatment of choice during pregnancy and lactation.
6. Conclusion
SAD is a prevalent and disabling disorder that often remains undetected unless the clinicaian takes a careful history. Present consensus supports that SSRIs can currently be regarded as first-line treatment in SAD because of their proven efficacy, tolerability and bility to treat co-morbid conditions such as depression or other anxiety disorders (Stein, 2003; Blanco et al., 2003; Ballenger et al., 1998). There is a recent evidence venlafaxine XR may also be considered in the first-line. Second-line treatments include MAOIs (e.g. phenelzine) and RIMAs (e.g.moclobemide).
The combination of CBT and an SSRI is often espoused as best practice, unfortunately there is little hard evidence supporting this (despite considerable face validity). Future studies taking a good look at combination therapies of this type are encouraged and also future research should focus on complicated and treatment refractory SAD and treatment strategies in special populations (e.g.children and adolescents).
References
- 1.
Agosti V. Nunes E. Levin F. 2002 28 643 652 - 2.
Allgulander C. Mangano R. Zhang J. et al. 2004 19 387 396 - 3.
Alonso J. Angermeyer M. C. Bernert S. Bruff aerts. R. Brugha T. S. Bryson H. de Girolamo G. Graaf R. Demyttenaere K. Gasquet I. Haro J. M. Katz S. J. Kessler R. C. Kovess V. Lepine J. P. Ormel J. Polidori G. Russo L. J. Vilagut G. Almansa J. Arbabzadeh-Bouchez S. Autonell J. Bernal M. MA Buist-Bouwman Codony. M. Domingo-Salvany A. Ferrer M. Joo S. S. et al. 2004 420 38 46 - 4.
Alpert J. E. Uebelacker L. A. Mc Lean N. E. AA Nierenberg Pava. J. A. Worthington J. J. I. I. I. Tedlow J. R. Rosenbaum J. F. Fava M. Social phobia. avoidant personality. disorder atypical depression. co-occurrence clinical implications. 1997 27 627 633 - 5.
Baldwin D. Bobes J. Stein D. J. et al. 1999 175 120 6 - 6.
Ballenger J. C. Davidson J. A. Lecrubier Y. et al. 1998 Suppl.): 54S-60S. - 7.
Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry2001 Suppl. 12: 5S-9S. - 8.
Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol2002 16 365 368 - 9.
Beesdo K. Bittner A. Pine D. S. Stein M. B. Höfler M. Lieb R. et al. 2007 64 903 912 - 10.
Beidel DC, Turner SM, Morris TL. Behavioral treatment of childhood social phobia. J Consult Clin Psychol2000 68 1072 80 - 11.
Beidel DC, Turner SM, Morris TL. Psychopathology of childhood social phobia. J Am Acad Child Adolesc Psychiatry1999 Suppl.6 643 50 - 12.
Beidel DC, Turner SM. Shy children, phobic adults: nature and treatment of social phobia. Washington, DC: American Psychological Association,1998 - 13.
Black B. Uhde T. W. ME Tancer 1992 12 293 5 - 14.
Black B. Uhde T. W. 1995 34 847 856 - 15.
Blanco C. Schineider F. R. Schmidt A. et al. 2003 18 1 29 40 - 16.
Bouwer C. Stein D. J. 1998 49 79 82 - 17.
MJ Briggs-Gowan Horwitz. S. M. Schwab-Stone M. et al. 2000 39 841 9 - 18.
Brown S. M. Peet E. Manuck S. B. Williamson D. E. Dahl R. E. Ferrell R. E. Hariri A. R. A. regulatory variant. of the. human tryptophan. hydroxylase gene biases. amygdala reactivity. 2005 10 884 888 - 19.
Buckner JD, Bonn-Miller MO, Zvolensky MJ et al., 2007 , Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav;32 2238 2252 - 20.
Buckner JD, Schmidt NB, Lang AR et al. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res2008a 42 230 239 - 21.
Buckner JD, Schmidt NB. Marijuana effect expectancies: relations to social anxiety and marijuana use problems. Addict Behav2008b 33 1477 1483 - 22.
Busch B. Biederman J. Cohen L. et al. Correlates of. A. D. H. D. among children. in pediatric. psychiatric clinics. 2002 53 1103 11 - 23.
Chavira D. A. Stein M. B. Bailey K. et al. 2004 20 155 64 - 24.
Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: An open trial. J Am Acad Child Adolesc Psychiatry2001 40 5 564 571 - 25.
Connor KM, Davidson JRT, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry2000 176 379 86 - 26.
Costello EJ. Child psychiatric disorders and their correlates: a primary care pediatric sample. J Am Acad Child Adolesc Psychiatry1989 28 851 5 - 27.
Davidson J. R. Miner C. M. De Veaugh-Geiss J. et al. 1997 27 1 161 6 - 28.
Davis M. Myers K. M. Chhatwal J. Ressler K. J. 2006 - 29.
Depping A. M. Komossa K. Kissling W. Leucht S. 2010 CD008120. - 30.
Dummit ESI, Klein RG, Tancer NK, et al. Systematic assessment of 50 children with selective mutism. J Am Acad Child Adolesc Psychiatry1997 36 653 660 - 31.
Dilbaz N. Güz H. 2 6 October2001 - 32.
Dilbaz N. 24 29 2002 - 33.
Dilbaz N. Güz H. 2002 39 79 86 Turkish) - 34.
Dilbaz N. 2005 Turkish) - 35.
Emmanuel N. Johnson M. Villareal G. et al. 1997 Kohala Coast, Hawaii. - 36.
Emmanuel N. P. Brawman-Mintzer O. Morton W. A. Book S. W. Johnson M. R. Lorberbaum J. P. Ballenger J. C. Lydiard R. B. Bupropion-S R. in treatment. of social. phobia 2000 12 2 111 3 - 37.
BA Erwin Heimberg. R. G. Juster H. Mindlin M. 2002 40 19 35 - 38.
CA Essau Conradt. J. Petermann F. 1999 37 831 43 - 39.
Federoff I. C. Taylor S. 2001 21 311 24 - 40.
Fehm L. Pelissolo A. Furmark T. Wittchen H. U. 2005 15 453 462 - 41.
Flannery-Schroeder E. C. Kendall P. 2000 24 251 78 - 42.
Furmark T. Tillfors M. Garpenstrand H. Marteinsdottir I. Langstrom B. Oreland L. Fredrikson M. 2004 362 189 192 - 43.
Furmark T. 2009 46 1 5 12 - 44.
Gelernter C. S. Uhde T. W. Cimbolic P. et al. 1991 48 938 45 - 45.
Gould R. Otto M. Pollack M. Yap L. 1997 - 46.
Graeff FG. On serotonin and experimental anxiety. Psychopharmacology2002 163 467 476 - 47.
Grant B. F. DS Hasin Blanco. C. et al. 2005 66 1351 1361 - 48.
Grant KA, Shively CA, Nader MA, Ehrenkaufer RL, Line SW, Morton TE, Gage HD, Mach RH. Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse1998 29 80 83 - 49.
Hariri A. R. Holmes A. 2006 10 182 191 - 50.
Heimberg R. G. Stein M. B. Hiripi E. et al. 2000 15 29 37 - 51.
Hirshfeld-Becker D. R. Biederman J. Henin A. Faraone S. V. Davis S. Harrington K. Rosenbaum J. F. 2007 28 225 233 - 52.
Hope DA, Heimberg RG, Bruch MA. Dismantling cognitive behavioral group therapy for social phobia. Behav Res Ther1995 33 637 50 - 53.
Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: A systematic review. Expert Rev Neurother2008 8 235 257 - 54.
Jackson A. 1995 119 4 399 404 - 55.
Katzelnick D J, Greist JH. Social anxiety disorder: an unrecognized problem in primary care. J Clin Psychiatry2001 Suppl.):11 6 - 56.
Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry1995 152 1368 71 - 57.
Keith J. R. Pitts R. C. Pezzuit T. et al. 2003 14 1 67 75 - 58.
Kessler R. C. Crum R. M. Warner L. A. Nelson C. B. Schulenberg J. Anthony J. C. 1997 54 313 321 - 59.
Kessler R. C. Stang P. Wittchen H. U. Stein M. EE Walters 1999 29 555 567 - 60.
Kessler R. C. Berglund P. Demler O. Jin R. Merikangas K. R. Walters E. E. 2005 6 593 602 - 61.
Kumpulainen K. Rasanen E. Raaska H. Somppi V. 1998 7 24 29 - 62.
Lanzenberger R. R. Mitterhauser M. Spindelegger C. Wadsak W. Klein N. Mien L. K. Holik A. Attarbaschi T. Mossaheb N. Sacher J. Geiss-Granadia T. Kletter K. Kasper S. Tauscher J. Reduced serotonin. receptor A. binding in. social anxiety. disorder 2007 61 1081 1089 - 63.
Lecrubier Y. Weiller E. 1997 17 21 - 64.
Lewinsohn P. M. Hops H. Roberts R. E. et al. Adolescent psychopathology. I. 1993 102 133 44 - 65.
Liebowitz M. R. De Martinis N. A. Weihs K. et al. 2003 64 7 785 92 - 66.
Liebowitz M. R. Gelenberg A. J. Munjack D. 2005 62 190 198 - 67.
Liebowitz M. R. Schneier F. Campeas R. et al. 1992 49 290 300 - 68.
Liebowitz M. R. Stein M. B. Tancer M. et al. A. randomised double-blind. fixed-dose comparison. of paroxetine. placebo in. the treatment. of generalized. social anxiety. disorder 2002 63 66 74 - 69.
Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry1987 22 141 73 - 70.
Mancini C. Van Ameringen M. Oakman J. M. Farvolden P. 1999 10 33 39 - 71.
March Wells J. K. 2003 2003 426 46 - 72.
Mennin DS, Heimberg RG, Jack MS.Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response. J Anxiety Disord.2000 14 4 325 43 - 73.
Merikangas K. R. Angst J. 1995 - 74.
Meron Ruscio. A. Brown T. A. Chiu W. T. Sareen J. Stein M. B. Kessler R. C. 2008 38 15 28 - 75.
Morris EP, Stewart SH, Ham LS. The relationship between social anxiety disorder and alcohol use disorders: a critical review. Clin Psychol Rev2005 25 734 760 - 76.
Mörtberg E. 2006 - 77.
Mrakotsky C. Masek B. Biederman J. Raches D. Hsin O. Forbes P. de Moor C. De Maso D. R. Gonzalez-Heydrich J. 2008 22 1 88 97 - 78.
Naranjo CA, Knoke DM. The role of selective serotonin- reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry2001 Suppl.): 18S-25S. - 79.
Pallanti S. Querciolo L. Rossi A. et al. 1999 60 819 23 - 80.
Pande AC, Davidson JR, Jeff erson JW, et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol1999 19 341 348 - 81.
Pande AC, Feltner DE, Jeff erson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol2004 24 141 149 - 82.
Pini S. Cassano G. B. Simonini E. Savino M. Russo A. Montgomery S. A. 1997 - 83.
Prior M. Smart D. Sanson A. et al. 2000 39 461 468 - 84.
Richard I. H. Schiff er. R. B. Kurlan R. 1996 8 383 392 - 85.
Robinson H. M. Hood S. D. A. review of. Pharmacological treatments. 2007 3 95 122 - 86.
Schneier F. R. Johnson J. Hornig C. D. et al. Social phobia. comorbidity morbidity in. an epidemiologic. sample 1992 49 282 8 - 87.
Schneier F. R. Liebowitz M. R. Abi-Dargham A. Zea-Ponce Y. Lin-H S. Laruelle M. Low dopamine. D. receptor binding. potential in. social phobia. 2000 157 457 459 - 88.
Schneier F. R. Spitzer R. L. Gibbon M. Fyer A. J. Liebowitz M. R. 1991 32 496 502 - 89.
Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol.2010 25 5 302 4 - 90.
Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: Results from an open-label study. J Clin Psychiatry2005 66 540 542 - 91.
Serretti A. Calati R. Mandelli L. De Ronchi D. 2006 7 1659 1669 - 92.
Sheehan D. V. Harnett-Sheehan K. BA Raj 1996 Suppl. 3: 89S-95S. - 93.
Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol1998 18 132 135 - 94.
Smolka M. N. Schumann G. Wrase J. Grusser S. M. Flor H. Mann K. Braus D. F. Goldman D. Buchel C. Heinz A. Catechol 2005 25 836 842 - 95.
Stein D. J. Cameron A. Amrein R. et al. 2002 Jul;17 4 161 70 - 96.
Stein D. J. Kasper S. Andersen E. W. et al. 2005 20 4 175 81 - 97.
Stein DJ. Algorithm for the pharmacotherapy of anxiety disorders. Curr Psychiatry Rep2003 - 98.
Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double blind placebo-controlled study. Am J Psychiatry1999 156 756 60 - 99.
Stein M. B. Gelernter J. Smoller J. W. 1994 197 214 - 100.
Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine in the treatment of generalized social phobia (social anxiety disorder): a randomised, double-blind, placebo-controlled study JAMA1998 280 708 13 - 101.
Steinhausen H. C. Juzi C. Selective mutism. an analysis. of 1. cases 1996 35 606 14 - 102.
Stern R. G. Petti T. A. Bopp K. Tobia A. 2009 29 3 206 9 - 103.
Tancer ME. Neurobiology of social phobia. J Clin Psychiatry1993 suppl12 26 30 - 104.
Thase M. E. 2007 Suppl. 8), 11-16. - 105.
Tiihonen J. Kuikka J. Bergstrom K. Lepola U. Koponen H. Leinonen E. 1997 154 239 242 - 106.
Tillfors M. Ekselius L. 2009 46 25 33 - 107.
Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol1994 62 350 358 - 108.
Vaishnavi S. Alamy S. Zhang W. Connor K. M. Davidson J. R. 2007 31 7 1464 9 - 109.
Van Ameringen M. Mancini C. Pipe B. Bennett M. 2004 9 753 762 - 110.
Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double- blind, placebo-controlled study. Am J Psychiatry2001 158 275 81 - 111.
Van Vliet IM, den Boer JA, Westenberg HGM. Psycho-pharmacological treatment of social phobia: a double-blind, placebo.controlled study with fluvoxamine. Psychopharmacology (Berl)1994 115 128 34 - 112.
Versiani M. Nardi A. E. Mundim F. D. et al. 1992 161 353 60 - 113.
Vulink N. C. Figee M. Denys D. 2011 Feb 21. [Epub ahead of print] - 114.
Wittchen H. U. Nelson C. B. Lachner G. 1998 28 109 26 - 115.
Wlazlo Z. Schroeder-Hartwig K. Hand I. Kaiser G. Munchau N. 1990 - 116.
Wren F. J. Scholle S. H. Heo J. et al. 2003 33 1 16 - 117.
Zaider TI, Heimberg RG. Non-pharmacologic treatments for social anxiety disorder. Acta Psychiatr Scand Suppl2003 S-84S - 118.
Zhang W. Connor K. M. Davidson J. R. 2005 19 551 553